Roche investor science event from ADA 2010
Phase III data on RG1583(taspoglutide) GLP-1 analogue and overall update on Roche´s franchise in diabetes & metabolism
Monday, 28 June 2010, Orlando, USA
Event to present and discuss new phase III data and results on RG1583(taspoglutide) GLP-1 analogue presented during the 2010 ADA (American Diabetes Association) 70th Scientific Sessions. Further, Roche will provided an overall update on its franchise in diabetes and metabolism.
Download mp3 file